Logo image of ALCRB.PA

CARBIOS (ALCRB.PA) Stock Fundamental Analysis

EPA:ALCRB - Euronext Paris - Matif - FR0011648716 - Common Stock - Currency: EUR

5.9  0 (0%)

Fundamental Rating

2

ALCRB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 63 industry peers in the Chemicals industry. ALCRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALCRB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALCRB has reported negative net income.
ALCRB had a negative operating cash flow in the past year.
In the past 5 years ALCRB reported 4 times negative net income.
In the past 5 years ALCRB always reported negative operating cash flow.
ALCRB.PA Yearly Net Income VS EBIT VS OCF VS FCFALCRB.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

ALCRB's Return On Assets of -11.21% is on the low side compared to the rest of the industry. ALCRB is outperformed by 73.02% of its industry peers.
ALCRB has a Return On Equity of -14.55%. This is in the lower half of the industry: ALCRB underperforms 68.25% of its industry peers.
Industry RankSector Rank
ROA -11.21%
ROE -14.55%
ROIC N/A
ROA(3y)-7.33%
ROA(5y)-10.2%
ROE(3y)-10.39%
ROE(5y)-14.21%
ROIC(3y)N/A
ROIC(5y)N/A
ALCRB.PA Yearly ROA, ROE, ROICALCRB.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 -20 30

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALCRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCRB.PA Yearly Profit, Operating, Gross MarginsALCRB.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K -100K

More info and screens

5

2. Health

2.1 Basic Checks

ALCRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALCRB has more shares outstanding
The number of shares outstanding for ALCRB has been increased compared to 5 years ago.
Compared to 1 year ago, ALCRB has an improved debt to assets ratio.
ALCRB.PA Yearly Shares OutstandingALCRB.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ALCRB.PA Yearly Total Debt VS Total AssetsALCRB.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 0.70, we must say that ALCRB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.70, ALCRB is doing worse than 74.60% of the companies in the same industry.
ALCRB has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALCRB (0.17) is better than 82.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 0.7
ROIC/WACCN/A
WACC6.78%
ALCRB.PA Yearly LT Debt VS Equity VS FCFALCRB.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 7.52 indicates that ALCRB has no problem at all paying its short term obligations.
ALCRB has a better Current ratio (7.52) than 96.83% of its industry peers.
ALCRB has a Quick Ratio of 7.45. This indicates that ALCRB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.45, ALCRB belongs to the best of the industry, outperforming 98.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.52
Quick Ratio 7.45
ALCRB.PA Yearly Current Assets VS Current LiabilitesALCRB.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.95% over the past year.
Looking at the last year, ALCRB shows a decrease in Revenue. The Revenue has decreased by -4.94% in the last year.
Measured over the past years, ALCRB shows a very negative growth in Revenue. The Revenue has been decreasing by -53.32% on average per year.
EPS 1Y (TTM)23.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.34%
Revenue 1Y (TTM)-4.94%
Revenue growth 3Y-42.76%
Revenue growth 5Y-53.32%
Sales Q2Q%265%

3.2 Future

The Earnings Per Share is expected to grow by 23.21% on average over the next years. This is a very strong growth
ALCRB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 166.53% yearly.
EPS Next Y-12.36%
EPS Next 2Y-4.85%
EPS Next 3Y-1.16%
EPS Next 5Y23.21%
Revenue Next Year-73.41%
Revenue Next 2Y175.33%
Revenue Next 3Y200%
Revenue Next 5Y166.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALCRB.PA Yearly Revenue VS EstimatesALCRB.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
ALCRB.PA Yearly EPS VS EstimatesALCRB.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCRB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCRB.PA Price Earnings VS Forward Price EarningsALCRB.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCRB.PA Per share dataALCRB.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.85%
EPS Next 3Y-1.16%

More info and screens

0

5. Dividend

5.1 Amount

ALCRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARBIOS

EPA:ALCRB (3/7/2025, 7:00:00 PM)

5.9

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)10-02 2024-10-02
Earnings (Next)04-11 2025-04-11/amc
Inst Owners23.25%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap99.42M
Analysts83.64
Price Target21.42 (263.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-13.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-92.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1291.1
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-3.95
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0
BVpS12.91
TBVpS10.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.21%
ROE -14.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.33%
ROA(5y)-10.2%
ROE(3y)-10.39%
ROE(5y)-14.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 562.84%
Cap/Sales 53228.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.52
Quick Ratio 7.45
Altman-Z 0.7
F-Score4
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)335.13%
Cap/Depr(5y)446.16%
Cap/Sales(3y)42474.8%
Cap/Sales(5y)26124.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.34%
EPS Next Y-12.36%
EPS Next 2Y-4.85%
EPS Next 3Y-1.16%
EPS Next 5Y23.21%
Revenue 1Y (TTM)-4.94%
Revenue growth 3Y-42.76%
Revenue growth 5Y-53.32%
Sales Q2Q%265%
Revenue Next Year-73.41%
Revenue Next 2Y175.33%
Revenue Next 3Y200%
Revenue Next 5Y166.53%
EBIT growth 1Y-27.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.7%
EBIT Next 3Y2.24%
EBIT Next 5Y32.32%
FCF growth 1Y-152.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-137.2%
OCF growth 3YN/A
OCF growth 5YN/A